Quick Answer
Werewolf Therapeutics, Inc. reported Stockholders Equity of $24.80 million for fiscal year 2025.
Werewolf Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $24.80M | -66.2% |
| 2024 | $73.39M | -34.1% |
| 2023 | $111.37M | -9.0% |
| 2022 | $122.34M | -19.9% |
| 2021 | $152.79M | +394.6% |
| 2020 | -$51.86M | -113.4% |
| 2019 | -$24.30M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $29.61M | -66.9% | -28.6% |
| June 30, 2025 | $41.46M | -60.1% | -27.6% |
| March 31, 2025 | $57.31M | -51.3% | -21.9% |
| December 31, 2024 | $73.39M | -34.1% | -17.9% |
| September 30, 2024 | $89.38M | -20.5% | -14.1% |
| June 30, 2024 | $104.02M | -12.3% | -11.5% |
| March 31, 2024 | $117.59M | -2.9% | +5.6% |
| December 31, 2023 | $111.37M | -9.0% | -1.0% |
- Werewolf Therapeutics, Inc. showed a decrease of -66.2% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, Werewolf Therapeutics, Inc.’s stockholders equity has grown by 202.1% (from -$24.30 million to $24.80 million).
- The most recent figure is from Werewolf Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: